Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
A6NNB3

UPID:
IFM5_HUMAN

ALTERNATIVE NAMES:
Bone-restricted interferon-induced transmembrane protein-like protein; Dispanin subfamily A member 1

ALTERNATIVE UPACC:
A6NNB3

BACKGROUND:
The protein Interferon-induced transmembrane protein 5, with alternative names Bone-restricted interferon-induced transmembrane protein-like protein and Dispanin subfamily A member 1, is required for normal bone mineralization. Its function is pivotal in ensuring the structural stability and health of bones.

THERAPEUTIC SIGNIFICANCE:
Linked to Osteogenesis imperfecta 5, a disorder characterized by increased bone fragility, Interferon-induced transmembrane protein 5's gene mutations underscore its significance. Exploring this protein's function offers a promising pathway to developing novel treatments for individuals affected by this genetic condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.